Investor Relations Home
|IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.
|01/08/19||IRIDEX Announces Preliminary Operational and Financial Results for 2018 Fourth Quarter and Full Year|
|MOUNTAIN VIEW, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 29, 2018.
Shipped approximately 460 to 465 Cyclo G6® Glaucoma Laser Systems and 45,500 to 46,500 G6 probes in the full year 2018
Shipped approximately 119 to 124 Cyclo G6® Glaucoma Laser Systems and a record 12,000 to 13,000 G6 probes in the fourth quarter 2018
Total r... |
|12/04/18||IRIDEX Announces Departure of Chief Financial Officer and Reiterates Full Year 2018 Guidance|
|MOUNTAIN VIEW, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced Chief Financial Officer Atabak Mokari will leave the Company for a senior finance executive role at another company. Mokari has agreed to assist in the orderly transition of his CFO responsibilities and will leave the Company effective December 18, 2018. IRIDEX plans to search for a replacement.
“We would like to thank Atabak for his service throughout the significant transformation of... |
|11/01/18||IRIDEX Announces 2018 Third Quarter Financial Results and Raises Full Year 2018 Guidance|
|MOUNTAIN VIEW, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 29, 2018.
Third Quarter Highlights
Cyclo G6™ product revenue increased approximately 23% year-over-year
Shipped 10,400 G6 probes
Shipped 117 G6 laser systems
Total revenue of $11.3 million
Received FDA Clearance to introduce updated TruFocus LIO Premiere™ Laser Accessory to the U.S. Market
|10/25/18||IRIDEX to Participate in Upcoming Investor Conferences|
|MOUNTAIN VIEW, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in upcoming investor conferences.
IRIDEX’s management is scheduled to present at the Stephens NY Investment Conference on Wednesday, November 7th, 2018 at 4:00 pm Eastern Time.
IRIDEX’s management is scheduled to present at the Stifel Healthcare Conference in New York City on Tuesday, November 13th, 2018 at 3:30 pm Eastern Time.
Interested parties m... |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.